Fig. 2: Msi2 marks bcCML cells that are highly therapy resistant.

a, b Msi2-expressing (GFP^hi) cells are highly resistant to imatinib-induced cell death. a Representative histograms show frequency of live (Annexin V-) GFP^neg, GFP^lo and GFP^hi established lineage-negative bcCML cells after 7 h of imatinib (5 μM) or DMSO control treatment. b The average frequency of live (Annexin V-) GFP^hi and GFP^neg cells after 7 h of imatinib (500 nM or 5 μM) or DMSO control treatment. **P = 0.001 for 0 μM, **P = 0.002 for 0.5 μM, ****P < 0.0001 for 5 μM (n = 4 for each treatment condition and cell type). c, d Msi2-expressing (GFP^hi) cells are highly resistant to radiation-induced cell death. c Representative histograms show frequency of live (Annexin V-) GFP^neg, GFP^lo and GFP^hi established lineage-negative bcCML cells 7 h following radiation (5 Gy). d The average frequency of live (Annexin V-) GFP^hi and GFP^neg cells 7 h following radiation (0, 5, or 10 Gy). *P = 0.01, **P = 0.003, ****P < 0.0001 (n = 3 for each treatment condition and cell type). e Representative live animal imaging of the calvarium after the establishment of GFP⁺ bcCML; green, donor mouse: actin GFP lin⁻ bcCML, red, recipient mouse: actin dsRed (See also Supplementary Movie 1). Two-tailed unpaired Student’s t-tests were used to determine statistical significance. Source data are provided as a Source Data File.